{"component": "definition", "props": {"groups": [{"size": 9, "snippet": "or \u201cCompound\u201d means, with respect to (a) the Recipient, the Recipient Study Drug, as monotherapy, and (b) BMS, the BMS Study Drug, as monotherapy.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [21, 36]}, {"key": "the-recipient", "type": "clause", "offset": [41, 54]}, {"key": "recipient-study-drug", "type": "definition", "offset": [60, 80]}, {"key": "bms-study-drug", "type": "definition", "offset": [115, 129]}], "samples": [{"hash": "4VulMtu6aOr", "uri": "/contracts/4VulMtu6aOr#single-agent-compound", "label": "Clinical Trial Collaboration and Supply Agreement (Replimune Group, Inc.)", "score": 31.4202594757, "published": true}, {"hash": "i3DmSZuwT59", "uri": "/contracts/i3DmSZuwT59#single-agent-compound", "label": "Clinical Trial Collaboration and Supply Agreement (Idera Pharmaceuticals, Inc.)", "score": 30.3305950165, "published": true}, {"hash": "hxUnX9zbQn5", "uri": "/contracts/hxUnX9zbQn5#single-agent-compound", "label": "Clinical Trial Collaboration and Supply Agreement (Idera Pharmaceuticals, Inc.)", "score": 29.5831623077, "published": true}], "hash": "c57338a1d1823b1056e72b62be15194e", "id": 1}, {"size": 3, "snippet": "or \u201cCompound\u201d means: (a) with respect to Olema, the Olema Study Drug, as monotherapy, and (b) with respect to Novartis, the Novartis Study Drugs, as monotherapy.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [25, 40]}, {"key": "study-drugs", "type": "definition", "offset": [133, 144]}], "samples": [{"hash": "bT28Q9D3o7e", "uri": "/contracts/bT28Q9D3o7e#single-agent-compound", "label": "Clinical Collaboration and Supply Agreement (Olema Pharmaceuticals, Inc.)", "score": 34.3497619629, "published": true}, {"hash": "1oFiJlfMzmf", "uri": "/contracts/1oFiJlfMzmf#single-agent-compound", "label": "Clinical Collaboration and Supply Agreement (Olema Pharmaceuticals, Inc.)", "score": 31.8281993866, "published": true}, {"hash": "dBbhAh50rX4", "uri": "/contracts/dBbhAh50rX4#single-agent-compound", "label": "Clinical Collaboration and Supply Agreement (Olema Pharmaceuticals, Inc.)", "score": 31.7214241028, "published": true}], "hash": "fb69c40d929574a8fd5f53fbf8e14bd5", "id": 2}, {"size": 3, "snippet": "or \u201cCompound\u201d shall mean, (a) with respect to Nektar, the Nektar Compound, and (b) with respect to BMS, the BMS Compound.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [30, 45]}, {"key": "nektar-compound", "type": "definition", "offset": [58, 73]}, {"key": "bms-compound", "type": "definition", "offset": [108, 120]}], "samples": [{"hash": "3aNXcgZBpWo", "uri": "/contracts/3aNXcgZBpWo#single-agent-compound", "label": "Clinical Trial Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "6A5yYIVm8Lq", "uri": "/contracts/6A5yYIVm8Lq#single-agent-compound", "label": "Clinical Trial Collaboration Agreement (Nektar Therapeutics)", "score": 27.8418884277, "published": true}, {"hash": "a7Jv6AOfnzx", "uri": "https://ir.nektar.com/static-files/d327b023-b662-4871-969c-eff636368d7d", "label": "ir.nektar.com", "score": 14.9489822388, "published": false}], "hash": "f248ac101ee2ef0de759c01ae1f30228", "id": 3}, {"size": 3, "snippet": "or \u201cCompound\u201d shall mean, (a) with respect to BioXcel, the BioXcel Compound, (b) with respect to Nektar, the Nektar Compound, and (c) with respect to the supplier of the CPI Compound, the CPI Compound.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [30, 45]}, {"key": "nektar-compound", "type": "definition", "offset": [109, 124]}, {"key": "to-the-supplier", "type": "clause", "offset": [147, 162]}], "samples": [{"hash": "hkEG81RH3AB", "uri": "/contracts/hkEG81RH3AB#single-agent-compound", "label": "Clinical Trial Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "7vJwnIXqLcD", "uri": "/contracts/7vJwnIXqLcD#single-agent-compound", "label": "Clinical Trial Collaboration Agreement (BioXcel Therapeutics, Inc.)", "score": 29.8542098999, "published": true}, {"hash": "kC67qzvlZLP", "uri": "https://ir.bioxceltherapeutics.com/static-files/0519c302-0784-4976-82c7-92247dcca2eb", "label": "ir.bioxceltherapeutics.com", "score": 10.0130052567, "published": false}], "hash": "99ff746f7793906b57c0cf043f3ec2a8", "id": 4}, {"size": 2, "snippet": "means, (a) with respect to Nektar, each Nektar Asset, and (b) with respect to BMS, each BMS Asset.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [11, 26]}], "samples": [{"hash": "gB8kfY3Kz6C", "uri": "/contracts/gB8kfY3Kz6C#single-agent-compound", "label": "Strategic Collaboration Agreement (Nektar Therapeutics)", "score": 29.353181839, "published": true}, {"hash": "cCp3KT0uDYx", "uri": "https://ir.nektar.com/static-files/fff0f320-3c22-4fc9-9a44-5187d8fc10a2", "label": "ir.nektar.com", "score": 10.1704311371, "published": false}], "hash": "29c74b9d6de930a458a8210868b5f4af", "id": 5}, {"size": 2, "snippet": "or \u201cCompound\u201d shall mean, (a) with respect to Five Prime, the Five Prime Compound, and (b) with respect to BMS, the BMS Compound.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [30, 45]}, {"key": "five-prime", "type": "definition", "offset": [46, 56]}, {"key": "bms-compound", "type": "definition", "offset": [116, 128]}], "samples": [{"hash": "BAUrzSRPL7", "uri": "/contracts/BAUrzSRPL7#single-agent-compound", "label": "Clinical Trial Collaboration Agreement (Five Prime Therapeutics Inc)", "score": 26.2073917389, "published": true}, {"hash": "eUg0TmBbFdr", "uri": "http://investor.fiveprime.com/static-files/1f56c0ae-267a-46b9-95c7-3e52e146583f", "label": "investor.fiveprime.com", "score": 10.1704311371, "published": false}], "hash": "20db1ed9d962b8b772ec85fd59ef231e", "id": 6}, {"size": 1, "snippet": "or \u201c Compound \u201d means: (a) with respect to the Recipient, the Recipient Study Drug, as monotherapy, and (b) with respect to BMS, the BMS Study Drug, as monotherapy.", "snippet_links": [{"key": "to-the-recipient", "type": "definition", "offset": [40, 56]}, {"key": "recipient-study-drug", "type": "definition", "offset": [62, 82]}, {"key": "bms-study-drug", "type": "definition", "offset": [133, 147]}], "samples": [{"hash": "g7SE7SvoFov", "uri": "https://d18rn0p25nwr6d.cloudfront.net/CIK-0001576263%20/275d3915-97af-417d-afec-89b5991f2739.pdf", "label": "d18rn0p25nwr6d.cloudfront.net", "score": 10.1704311371, "published": false}], "hash": "d1ee1c4d5e6243c2e05ea4dbf7a94131", "id": 7}, {"size": 1, "snippet": "means, (a) with respect to Exelixis, the Exelixis Compound, and (b) with respect to Roche, the Roche Compound, in each case as a monotherapy.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [11, 26]}, {"key": "roche-compound", "type": "definition", "offset": [95, 109]}, {"key": "each-case", "type": "definition", "offset": [114, 123]}], "samples": [{"hash": "eTSbf4BFsuO", "uri": "/contracts/eTSbf4BFsuO#single-agent-compound", "label": "Joint Clinical Research Agreement (Exelixis, Inc.)", "score": 31.1492137909, "published": true}], "hash": "46d30ab1802b3d6f7a6846d74296cc13", "id": 8}, {"size": 1, "snippet": "means, (a) with respect to \u2587\u2587\u2587\u2587\u2587\u2587\u2587, the 435 Compound or the 055 Compound (each hereinafter, a \u201c\u2587\u2587\u2587\u2587\u2587\u2587\u2587 Compound\u201d), and (b) with respect to Idenix, the Idenix Compound.", "snippet_links": [{"key": "with-respect-to-\u2587", "type": "clause", "offset": [11, 28]}], "samples": [{"hash": "isbAN2l2plP", "uri": "/contracts/isbAN2l2plP#single-agent-compound", "label": "Clinical Trial Collaboration Agreement (Idenix Pharmaceuticals Inc)", "score": 24.151266098, "published": true}], "hash": "4003cd6c7559b4a75ba4e43bcd37b8fc", "id": 9}, {"size": 1, "snippet": "Defined Term Section Alliance Manager 2.6 Breaching Party 12.2(a) CDA 9.1 Tyrosine Kinase Inhibitor Trial 5.4(d) Co-Chair 2.3(a) Cure Period 12.2(a) Dispute 13.3(a) Exclusive Discussion Period 5.4(d) GAAP 4.1(a)", "snippet_links": [{"key": "defined-term-section", "type": "clause", "offset": [0, 20]}, {"key": "alliance-manager", "type": "definition", "offset": [21, 37]}, {"key": "breaching-party", "type": "definition", "offset": [42, 57]}, {"key": "cure-period", "type": "definition", "offset": [129, 140]}, {"key": "discussion-period", "type": "definition", "offset": [175, 192]}], "samples": [{"hash": "hhuufthjJvq", "uri": "/contracts/hhuufthjJvq#single-agent-compound", "label": "Clinical Trial Collaboration Agreement", "score": 30.3408622742, "published": true}], "hash": "4120494ef0379ebd40a45b1946f01009", "id": 10}], "next_curs": "CmISXGoVc35sYXdpbnNpZGVyY29udHJhY3Rzcj4LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIec2luZ2xlLWFnZW50LWNvbXBvdW5kIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 27, "snippet": "or \u201cCompound\u201d means, with respect to (a) the Recipient, the Recipient Study Drug, as monotherapy, and (b) BMS, the BMS Study Drug, as monotherapy.", "title": "Single Agent Compound", "id": "single-agent-compound", "examples": ["Each Party represents and warrants that, to the best of its knowledge, it is not aware of any material safety or toxicity issue with respect to its <strong>Single Agent Compound</strong> that are not reflected in the investigator\u2019s brochure for its <strong>Single Agent Compound</strong> existing as of the Effective Date.", "Each Party shall provide a Right of Cross-Reference to its existing respective IND for its respective <strong>Single Agent Compound</strong> as necessary to allow the Combined Therapy Trials to be conducted under the Combined Therapy IND.", "The Recipient shall be the sole holder of all legal interests in the Combined Therapy IND; provided, however, that the Recipient may not grant any Third Party any Right of Cross-Reference with respect to any portion of the Combined Therapy IND pertaining to BMS\u2019s <strong>Single Agent Compound</strong> for use as monotherapy or for use in combination with any molecules, agents, antibodies or compounds other than the Recipient Study Drug.", "Each Party represents and warrants that, to the best of its knowledge as of the Effective Date, it is not aware of any material safety or toxicity issues with respect to its <strong>Single Agent Compound</strong> that are not reflected in the investigator\u2019s brochure for its <strong>Single Agent Compound</strong> existing as of the Effective Date.", "If the charged Party does not commence actions to defend such claim within [***] after request by the other Party to do so, then the other Party shall have the right, but not the obligation, to defend any such claim to the extent such claim pertains to the other Party\u2019s <strong>Single Agent Compound</strong>.", "Each Party represents and warrants as of the Effective Date that, to the best of its knowledge, it is not aware of any material safety or toxicity issue with respect to its <strong>Single Agent Compound</strong> that are not reflected in the investigator\u2019s brochure and/or safety information provided to the other Party for its <strong>Single Agent Compound</strong> existing as of the Effective Date.", "For the avoidance of doubt, each Party shall be responsible for (x) drafting and updating as necessary the investigator\u2019s brochure for its respective <strong>Single Agent Compound</strong>, and (y) filing all necessary Regulatory Documentation to the existing IND for its respective <strong>Single Agent Compound</strong>, including the submission to such existing IND of serious adverse event and adverse drug reaction cases emerging from any Combined Therapy Trial.", "If a Party grants its or the other Party\u2019s Affiliate or a Third Party a license (other than a license solely to make a Product for a Party) to develop and commercialize its <strong>Single Agent Compound</strong> on a worldwide basis or in any geographic region and/or for all purposes or a limited field, (a \u201cLicensee\u201d), such Party will obtain the Licensee\u2019s agreement to abide by the terms of this Agreement in the same manner as the licensor Party.", "The Recipient shall be the sole holder of all legal interests in its IND; provided, however, that the Recipient may not grant any Third Party any Right of Cross-Reference with respect to any portion of its IND pertaining to BMS\u2019s <strong>Single Agent Compound</strong> for use as monotherapy or for use in combination with any molecules, agents, antibodies or compounds other than the Recipient Study Drug.", "Each Party represents and warrants as of the Effective Date that, to the best of its knowledge, it is not aware of any material safety or toxicity issue with respect to its <strong>Single Agent Compound</strong> that are not reflected in the investigator\u2019s brochure for its <strong>Single Agent Compound</strong> existing as of the Effective Date."], "related": [["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["exempt-compound", "Exempt compound", "Exempt compound"], ["milk-product", "Milk product", "Milk product"], ["licensed-compound", "Licensed Compound", "Licensed Compound"], ["reference-biological-product", "Reference biological product", "Reference biological product"]], "related_snippets": [], "updated": "2025-07-10T04:27:38+00:00"}, "json": true, "cursor": ""}}